By Joshua Kappel, Jeff Fitzgerald, Psychedelic Alpha
Feb 14, 2024
Colorado Natural Medicine Advisory Bulletins provide updates on the implementation of Colorado's legal psychedelics program, the Natural Medicine Health Act. Bulletin #8 focuses on updates on the NMAB's initial set of recommendations for the state’s regulated natural medicine program
By Jeremy Shaw, Sahar Ayinehsazian
Feb 13, 2024
The Corporate Transparency Act (CTA), effective January 1, 2024, requires many businesses to disclose ownership information. This Insights blog explains who needs to comply, what details to report, and key deadlines. Failing to comply can lead to fines or even imprisonment. Get help understanding exemptions and navigating the CTA's new reporting requirements to ensure your business stays compliant.
By David M. Ullian
Feb 13, 2024
Massachusetts launched the Cannabis Social Equity Trust Fund to aid qualified cannabis businesses disproportionately impacted by marijuana prohibition. Licensed businesses or applicants meeting specific criteria, like Social Equity Program participants, can access grants or loans (up to $50,000 now!). Apply online and learn more about future programs before the February 15th deadline.
By David M. Ullian
Feb 6, 2024
The South Carolina General Assembly is revisiting medical cannabis legalization in 2024 with the SCCCA. This revised bill would allow qualified patients with doctor recommendations to purchase limited amounts of infused and extracted cannabis products from licensed pharmacies. Additionally, South Carolina may soon regulate hemp-derived cannabinoids like Delta-8 and Delta-10 through a separate bill requiring licensing, testing, and age restrictions. This Insights post explores both initiatives and their potential impact on the state's future cannabis landscape.
By David M. Ullian
Feb 6, 2024
The North Carolina Legislature is expected to revisit medical cannabis access through the North Carolina Compassionate Care Act (NCCCA) once the legislative session begins in 2024. Public support is strong, and the bill would allow patients with debilitating conditions to purchase cannabis from licensed centers. Additionally, the state may soon regulate hemp-derived and kratom products, requiring licenses and testing for production and retail sales. Read this Insights post for more information on North Carolina’s Compassionate Care Act.
Commentary and analysis on cannabis, hemp, psychedelics, and other emerging therapies from the attorneys and policy specialists at the nation’s leading cannabis law firm.
